
    
      The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of
      topical administration of ISV-305 (0.1% dexamethasone in DuraSiteÂ® 2) compared with Vehicle
      when dosed twice daily for 1 day prior to surgery, the day of surgery and 14 days post
      cataract surgery.
    
  